Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib-Reference-Cited by-同舟云学术

Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib

Published:2017-12-08 Issue: Volume: Page:
ISSN:1582-1838
Container-title:Journal of Cellular and Molecular Medicine
language:en
Short-container-title:J. Cell. Mol. Med.

Author:

Giallongo Cesarina¹²,Parrinello Nunziatina L.¹,La Cava Piera¹,Camiolo Giuseppina¹,Romano Alessandra¹,Scalia Marina²,Stagno Fabio¹,Palumbo Giuseppe A.¹,Avola Roberto²,Li Volti Giovanni²,Tibullo Daniele²^ORCID,Di Raimondo Francesco¹

Affiliation:

1. Division of Hematology; A.O.U. Policlinico-OVE; University of Catania; Catania Italy

2. Department of Biomedical and Biotechnological Sciences; University of Catania; Catania Italy

Publisher

Wiley

Subject

Cell Biology,Molecular Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jcmm.13326/fullpdf

Reference33 articles.

1. Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy;Chomel;Oncotarget,2011

2. SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation;Giallongo;BMC Cancer,2013

3. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years;Lang;J Clin Pharm Ther,2015

4. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study;Ross;Blood,2013

5. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML;Branford;Blood,2013

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myeloid-derived suppressor cells: Implication in myeloid malignancies and immunotherapy;Acta Histochemica;2024-10

2. Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia;Pharmaceuticals;2024-07-05

3. Exploring the Complexity and Promise of Tumor Immunotherapy in Drug Development;International Journal of Molecular Sciences;2024-06-11

4. A Microchip For Exosome Isolation That Can Be Impregnated With Imatinib Simultaneously: An In Vitro Analysis;Russian Open Medical Journal;2024-03-25

5. Immunosenescence and cancer: Opportunities and challenges;Medicine;2023-11-24